



**Minnesota Department of Human Services DUR Board Meeting
March 4, 2026**

Members Present

Ann Philbrick, PharmD.

Daniel Holt, PharmD.

Samuel Houmes, PharmD.

DHS Staff Present

Chad Hope, PharmD., Pharmacy Program and Medicaid Decision Support Director

Erin Neumann, PharmD., BCPPS, Senior Pharmacist

Prime Therapeutics Staff Present

Laura Pounders, PharmD., Clinical Account Manager

Chloe Groomes, PharmD., Clinical Account Director

Kimberly Bauer, Business Analyst

Welcome

Laura Pounders, introduced both MN DHS and Prime staff. The meeting was started with a reminder to participants that the review and voting on items from the December meeting would be repeated due to a technical issue which had prevented members of the public from attending.

Public Comments

Kyle Knudsen with Axsome Therapeutics provided a 3 minute informational presentation on Symbravo. No questions were asked about the information provided.

Call to Order

Roll Call of DUR Board Members

Kimberly Bauer took attendance of Board Members.

Roll Call of DUR Board Members, March 4, 2026		
Attendance - DUR Board Members	Present	Absent
Philbrick, Ann, PharmD.	X	
Huskic, Arnes PharmD		X
Holt, Daniel, PharmD.	X	
Houmes, Samuel, PharmD.	X	

Approval of Previous Meeting Minutes

Laura Pounders asked for review and approval of the minutes from the September 10th, 2025 meeting. The minutes were attached to the meeting invite.

Approval of Previous Meeting Minutes			
Previous Meeting September 10, 2025			
Discussion: Approved as written			
Voting – DUR Board Members Does not include excused or unexcused members	Yes	No	Abstain
Philbrick, Ann, PharmD.	X		
Holt, Daniel, PharmD.	X		
Houmes, Samuel, PharmD.	X		

Old Business

Dr. Pounders reviewed a previously approved mailing for Atypical Antipsychotics in Children. Eighty letters were mailed to providers on October 10, 2025. A report on the financial and patient impact will be presented at a later board meeting.



New Business

Dr. Pounders reviewed the FirstIQ system used to calculate cost savings on DUR interventions. This system tracks identified cases and calculates an average cost per day at baseline and then again 6 months after the intervention occurs. The cost is calculated based on an assigned Standard Therapeutic Class. This methodology tracks cost savings based on pharmacy claims only, and it does not include any associated medical costs even if they relate to the activity.

Additionally, the SUPPORT Act scope and purpose was stated. This bill was passed in 2018 to provide for opioid use disorder prevention, recovery, and treatment. The Department of Health and Human Services addresses the required implementation of provisions, including requirements regarding opioid prescription claim reviews at the point of sale (POS) and retrospective reviews; the monitoring and management of antipsychotic medication in children; identification of processes to detect fraud and abuse; and mandatory DUR report updates, as well as requirements for Medicaid Managed Care Organizations (MCOs).

The SUPPORT Act Retro DUR activities were mailed on April 11th, 2025. All of these activities have a pre-intervention period (baseline) of 12/31/24-3/31/25 and a post intervention period of 10/1/25-1/31/26. For the patients who received two or more short acting opioids within 90 days, Prime sent out 380 letters to prescribers. This resulted in a 62% decrease in patients meeting this criteria from baseline to post-intervention and 47% decrease in average monthly cost. The final 3 activities were grouped together for reporting and consist of: patients who had six or more claims for opioids in the last 180 days and no claims for naloxone in the last year, with a diagnosis of opioid overdose or substance abuse

disorder in the last year; patients who had a claim for an opioid in the last 90 days with a claim for medication assisted treatment drug in the last two years or opioid use disorder in the last two years; and, members with a claim for a 30 day supply of two or more different opioids in the last 90 days that exceeded 90 MME. These 3 activities had 1574 prescribers prior to the intervention and decreased to 1171 prescribers during the post intervention period. This resulted in a 31% average monthly cost decrease.

RetroDUR #1 Overlapping use of Oral and Injectable Antipsychotics.

Dr. Pounders reviewed the proposed RetroDUR activity. The purpose of this is to identify members who may be utilizing both injectable and oral antipsychotics. Members of any age who have 3 or more claims for a long acting injectable and an oral antipsychotic in the last 90 days will be included in this provider lettering activity. Initial estimates show that there are currently around 839 claims that meet this criteria. This includes 105 members, 112 physicians, and 53 pharmacies. The proposed letter for this activity was presented to the board. The board approved RetroDUR activity number 1 without modification.

Approval of RetroDUR #1			
Overlapping use of Oral and Injectable Antipsychotics			
Discussion: Approved as written			
Voting – DUR Board Members Does not include excused or unexcused members	Yes	No	Abstain
Philbrick, Ann, PharmD.	X		
Holt, Daniel, PharmD.	X		
Houmes, Samuel, PharmD.	X		

RetroDUR Activity #2 Overutilization of Triptans

Dr. Pounders reviewed the second proposed RetroDUR activity with the board. The purpose of this activity is to identify members who may be utilizing more than 9 doses of triptans per month. A literature review shows that overutilization of triptans is defined as 10 or more days per month and can lead to adverse effects including medication overuse headaches (MOH). This provider mailing will include any member of any age with claims exceeding 9 doses of triptans in a 30 day period within the last 90 days. The intervention estimates show that this will include about 2441 claims. These claims represent 1696 members, 1241 physicians, and 657 pharmacies. The proposed letter for this activity was presented to the board. The board approved RetroDUR activity number 2 without modification.

Approval of RetroDUR #2			
Overutilization of Triptans			
Discussion: Approved as written			
Voting – DUR Board Members Does not include excused or unexcused members	Yes	No	Abstain
Philbrick, Ann, PharmD.	X		
Holt, Daniel, PharmD.	X		
Houmes, Samuel, PharmD.	X		

The board discussed the next meeting dates. There were no conflicts with June 3rd or June 24th.

The meeting was adjourned.